Elise C. Kohn

Also affiliated with National Cancer Institute, National Cancer Institute

MedicineBiochemistry, Genetics and Molecular BiologyChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 27 papers. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02011

N/A

2.6DataRank · unranked

88 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +16 more

Thapsigargin-Induced Gene Expression in Nonexcitable Cells Is Dependent on Calcium Influx

Molecular Endocrinology(1997)10.1210/mend.11.3.9894

N/A

1.6DataRank · unranked

34 citations

Robert P. Wersto, Susan Hobson, Elise C. Kohn, Karin D. Rodland

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Annals of Oncology(2023)10.1016/j.annonc.2023.10.047

N/A

0.500DataRank · unranked

27 citations

Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla +14 more

Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.07.031

N/A

0DataRank · unranked

31 citations

Christina M. Annunziata, John L. Hays, Liang Cao, Peter L. Choyke, Minshu Yu +8 more

Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6038

N/A

0DataRank · unranked

7 citations

Daniel An, Ann McCoy, Elise C. Kohn, Christina M. Annunziata, Kathryn Trewhitt +4 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

0DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4618

N/A

0DataRank · unranked

21 citations

Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore +13 more

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

The Lancet Oncology(2022)10.1016/s1470-2045(22)00139-5

N/A

0DataRank · unranked

142 citations

Antonio González-Martı́n, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Jean‐Emmanuel Kurtz +73 more

Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review

Gynecologic Oncology(2022)10.1016/j.ygyno.2021.12.032

N/A

0DataRank · unranked

15 citations

Eloise Chapman‐Davis, Navya Nair, David E. Cohn, Jeffrey F. Hines, Elise C. Kohn +2 more

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.19.02960

N/A

0DataRank · unranked

383 citations

Barbara M. Norquist, Christina Lacchetti, Deborah K. Armstrong, Rachel N. Grisham, Paul J. Goodfellow +7 more

Top advances of the year: Ovarian cancer

Cancer(2023)10.1002/cncr.35135

N/A

0DataRank · unranked

26 citations

Elise C. Kohn, William P. Tew, Melissa Lumish

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096

N/A

0DataRank · unranked

9 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5512

N/A

0DataRank · unranked

6 citations

Elizabeth Katherine Lee, Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, Andrea E. Wahner Hendrickson, D. Gulhan +14 more

Data from Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells

(2023)10.1158/1078-0432.c.6517819

N/A

0DataRank · unranked

0 citations

William J. LaRochelle, Haihong Zhong, Gulshan Ara, Joshua Cohen, Elise C. Kohn +1 more

Data from Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines

(2023)10.1158/1535-7163.c.6531095

N/A

0DataRank · unranked

0 citations

Jenny Llamas, Michele Gunsior, Laurent Ozbun, William C. Reinhold, Sudhir Varma +8 more

Data from Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells

(2023)10.1158/1078-0432.c.6517819.v1

N/A

0DataRank · unranked

0 citations

William J. LaRochelle, Haihong Zhong, Gulshan Ara, Joshua Cohen, Elise C. Kohn +1 more

Data from Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines

(2023)10.1158/1535-7163.c.6531095.v1

N/A

0DataRank · unranked

0 citations

Jenny Llamas, Michele Gunsior, Laurent Ozbun, William C. Reinhold, Sudhir Varma +8 more

Vaccination of Adults With Cancer: ASCO Guideline Clinical Insights

JCO Oncology Practice(2024)10.1200/op.24.00107

N/A

0DataRank · unranked

5 citations

Kari Bohlke, Elise C. Kohn, Mini Kamboj

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3877

N/A

0DataRank · unranked

8 citations

Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John +15 more

A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf089

N/A

0DataRank · unranked

5 citations

Dmitriy Zamarin, José R. Conejo-García, Kari Hacker, Roberto Vargas, Panagiotis A. Konstantinopoulos +6 more

State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report

JCO Precision Oncology(2022)10.1200/po.22.00355

N/A

0DataRank · unranked

8 citations

Katherine C. Fuh, Rebecca C. Arend, Gottfried E. Konecny, Panagiotis A. Konstantinopoulos, Kunle Odunsi +4 more

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.20.01924

N/A

0DataRank · unranked

315 citations

Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman +11 more

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

Cancer Cell(2020)10.1016/j.ccell.2020.10.015

N/A

0DataRank · unranked

104 citations

Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton +41 more

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6003

N/A

0DataRank · unranked

56 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +15 more

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa061

N/A

0DataRank · unranked

33 citations

Lou Staudt, Naoko Takebe, David A. Wheeler, Linghua Wang, Maria Cardenas +34 more